2例贝林妥欧单抗输注新模式的报告  

Novel outpatient infusion model of blinatumomab:case studies of two patients

作　　者：力桂君 蒋雪梅 王馨 徐秋霞 李建辉 代素思 何莹 易海 陈丹 LI Guijun;JIANG Xuemei;WANG Xin;XU Qiuxia;LI Jianhui;DAI Susi;HE Ying;YI Hai;CHEN Dan(Department of Hematology,General Hospital of Western Theater Command of the Chinese People′s Liberation Army,Chengdu 610000,China)

机构地区：[1]中国人民解放军西部战区总医院血液科,四川成都610000

出　　处：《中国输血杂志》2025年第4期557-561,共5页Chinese Journal of Blood Transfusion

摘　　要：目的通过总结2例关于贝林妥欧单抗(blinatumomab)在急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)患者中的院外输注新模式的案例,以解决患者舒适度差、医疗成本高、生活质量低的问题,为临床推广贝林妥欧单抗输注新模式提供参考依据。方法通过对本院2例异基因造血干细胞移植后患者的维持治疗案例进行分析,总结院外输注的新模式的效果,讨论院外输注的筛选标准、护理措施及标准操作流程,并系统梳理国内外相关输注进展。结果2例患者采用院外输注新模式后均未出现严重不良反应,初步验证了该模式的可行性和安全性。贝林妥欧单抗采用院外输注的新模式为患者提供了更便捷舒适的治疗选择,降低了医疗费用,并提高了患者生活质量。结论尽管目前案例较少,但初步结果证明了该新模式的潜力,其具有可行性。Objective To evaluate the feasibility of a novel outpatient infusion model for blinatumomab in two acute lymphoblastic leukemia(ALL)patients,aiming to address challenges of poor treatment tolerance,high healthcare costs,and compromised quality of life,thereby providing clinical insights for broader adoption of this approach.Methods Two post-allogeneic hematopoietic stem cell transplantation(allo-HSCT)patients undergoing blinatumomab maintenance therapy were selected to evaluate the efficacy of the outpatient infusion model.Patient selection criteria,nursing protocols,standardized workflows,and advancements in infusion practices were systematically analyzed combined with a review of global developments in this field.Results Both patients completed outpatient blinatumomab infusion without severe adverse events,demonstrating preliminary feasibility and safety of this model.The novel approach enhanced treatment convenience,reduced hospitalization costs,and improved quality of life.Conclusion Despite the limited sample size,this pilot study highlights the potential of outpatient blinatumomab administration as a viable alternative to traditional inpatient regimens.

关 键 词：贝林妥欧单抗 急性淋巴细胞白血病 院外输注 

分 类 号：R733.71[医药卫生—肿瘤] R457.1[医药卫生—临床医学]